Cell Therapy
Clinical Trials
Scaling Up

Chimeric and WuXi ATU Partner to Advance CAR-T Manufacturing Pipelines

Anna Osborne
13 April 2022
Clinical-stage cell therapy company, Chimeric Theraputics (Chimeric), has announced they have entered a strategic manufacturing partnership with the global contract testing and manufacturing organization, WuXi Advanced Therapies (WuXi ATU).

The initial five-year agreement will see Chimeric transfer part of their manufacturing and analytical testing technologies over to Wuxi ATU, who in turn will provide extensive cGMP knowledge for the development, testing and manufacturing of Chimeric’s therapeutic pipeline.

Leveraging on WuXi ATU’s manufacturing capabilities, Chimeric will accelerate and scale manufacturing of their two current CAR-T cell therapies, with plans to capitalize upon opportunities to manufacturing new CAR-T assets and support multiple, multi-center CAR-T clinical trials.

Initial focus will center on supporting the clinical development of Chimeric’s two CAR-T cell programs – CHM2101 and CHM1101, currently in late preclinical development for multiple GI cancers and a single-site Phase I trial for progressive or recurrent glioblastoma, respectively.

“We’re delighted to partner with Chimeric Theraputics to accelerate the development of two of their autologous CAR-T cell programs. These treatments offer much needed hope to patients with gastrointestinal cancers or glioblastoma, and we are honored to support Chimeric Theraputics as they prepare these treatments for further clinical testing,” said Dr. David Chang, CEO of WuXi Advanced Therapies.

Pre-clinical to clinical progression of CHM2101 will be supported by Wuxi ATU’s end-to-end platform for cGMP CAR-T manufacturing and testing, allowing for scalable readiness in line with its planned first-in-human study.

The current clinical program for CH1101 will utilize upon WuXi ATU’s scalable manufacturing capacity to expanded into additional clinical trials across multiple sites, and to investigate other solid tumor indications, including metastatic melanoma.

“With its extensive experience in cGMP manufacturing and analytical testing, as well as its seamless platform process for CAR-T cell production, WuXi ATU is uniquely positioned to support the acceleration and expansion of the CHM1101 and CHM2101 developmental programs,” commented Jennifer Chow, CEO of Chimeric Theraputics.

Source: Chimeric Theraputics Press Release